Bio

Robert Petitt focuses on capital markets, securities law, mergers and acquisitions (“M&A”), and corporate governance matters for both public and private company clients. Rob advises public issuers, underwriters, and placement agents in connection with a wide variety of capital markets transactions, including initial and follow-on public offerings, at-the-market offerings, registered direct offerings, and PIPEs, and draws on his extensive securities law experience to assist with ongoing SEC reporting obligations, including proxy statements, 10-Ks, and 10-Qs. Rob also guides public company boards on a full spectrum of governance issues and best practices, including compliance with applicable Nasdaq and NYSE standards. Rob has represented buyers and sellers in a variety of complex M&A transactions and takes pride in effectively and efficiently representing his clients’ interests. Rob works closely with the boards and management teams of public companies across a wide variety of industries, including pharmaceutical and medical device companies, software companies, less-lethal defense companies, REITs, and ancillary cannabis companies. He began his career at a Boston-based Am Law 50 firm, where he advised REITs and other public issuers on corporate governance matters and represented public company acquirers in several multibillion-dollar M&A transactions.